<DOC>
	<DOC>NCT00446784</DOC>
	<brief_summary>CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate</brief_summary>
	<brief_title>Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adults patients with rheumatoid arthritis Patients who have received stable weekly doses of oral methotrexate (5 to 25 mg/week administered as a single dose) for a minimum of 28 days (4 weeks/4 doses) History of chronic infectious disease such as genitourinary, pulmonary or sinus infections. Any current or known malignancy or history of malignancy within the previous 5 years Pregnant or lactating women; women of childbearing potential who are unwilling to unable to use an acceptable method of birth control during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>